Regeneron Pharmaceuticals (REGN) Total Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $9.4 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 15.78% year-over-year to $9.4 billion in Q1 2026; TTM through Mar 2026 was $9.4 billion, a 15.78% increase from a year earlier, with the FY2025 full-year figure at $9.3 billion, up 10.66% from the prior year.
• Total Liabilities advanced to $9.4 billion in Q1 2026 per REGN's latest filing, from $9.3 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $9.4 billion in Q1 2026 and bottomed at $6.2 billion in Q3 2022.
• The 5-year median for Total Liabilities is $7.4 billion (2024), against an average of $7.6 billion.
• Across the five-year window, Total Liabilities declined 2.72% in 2022 and gained 18.7% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $6.6 billion in 2022, then gained by 8.5% to $7.1 billion in 2023, then advanced by 18.27% to $8.4 billion in 2024, then climbed by 10.66% to $9.3 billion in 2025, then gained by 1.54% to $9.4 billion in 2026.
• Per Business Quant, the three latest REGN Total Liabilities figures stand at $9.4 billion (Q1 2026), $9.3 billion (Q4 2025), and $9.2 billion (Q3 2025).